Taille du marché mondial, prévisions et tendances marquantes sur 2023-2035
The Oligonucleotide API Market is expected to reach USD 5 billion by the end of 2035, growing at a CAGR of 10% during the forecast period, i.e., 2023-2035. In 2022, the Oligonucleotide API industry size was over USD 2 Million. The growth of the market can be attributed to the increasing laboratory and research institute experiments across the globe. The increasing use of oligonucleotides for various applications such as gene editing, diagnostics, therapeutics, etc., has led to the growing interest in APIs across organizations. According to World Bank data, in 2018, there were 1,597 researchers per million people engaged in research and development activities worldwide, an increase from 2015 (1,412 researchers per million). Moreover, the increasing use of oligonucleotides in the effective treatment of several disorders is another important factor that is expected to further drive the market growth throughout the forecast period.
In addition to these factors, which are expected to fuel the growth of the oligonucleotide API market include the global increasing proportion of oligonucleotide API in the drug pipeline which is estimated to accelerate the global oligonucleotide API market size in the coming years. Oligonucleotide is a new type of therapeutic molecule ideal for treating a variety of diseases. The base of oligonucleotide is paired with DNA or RNA to form a structure. In PCR (polymerase chain reaction), oligonucleotides are commonly used as primers. Moreover, funding for life science activities, launch of innovative products and drug discovery, and investments in large-scale scientific projects are expected to drive the demand for oligonucleotide API during the forecast period. For example, it is estimated that governments around the world and international organizations are expected to invest a total of more than $170 billion in large-scale science projects between 2022 and 2025.
Secteur de l'API à l'oligonucléotide : moteurs de croissance et défis
Growth factors
- Rising Prevalence of Cancer and Neurodegenerative Diseases - According to the National Cancer Institute, in 2020, there were 1,806,590 new cancer diagnoses in the United States and 606,520 cancer deaths. The increasing number of cancer cases is propelling the demand for advanced screening procedures. Moreover, the treatment of neurodegenerative diseases also requires a personalized approach. In terms of neurodegenerative conditions, Alzheimer’s disease is one of the most common. There are several limitations associated with conventional medicine in this field, so oligonucleotide APIs are being studied extensively. This factor is expected to increase the global oligonucleotide API market size during the forecast period.
- Percentage Growth of API Manufacturing Facilities – According to the U.S. Food & Drug Administration (FDA), there were over 28% of U.S.-based API manufacturing facilities in 2019 serving the U.S. market.
- An increase in medical approval programs for oligonucleotides - It was observed that in 2019, approximately 605 oligonucleotide approval programs were under development worldwide, compared to only 200 in 2010.
- Health spending on the rise Worldwide - Global health spending amounted to $9.83 trillion in 2019 according to data provided by the World Bank, an increase from $9.7 billion in 2018.
- Global per capita income rises - The World Bank reported that global annual per capita income increased by 4.8% in 2021, up from 1.5% in 2020.
% in 2019.
Challenges
- High Oligonucleotide-Associated Waste Generation - Yes. The current state of the art in oligonucleotide synthesis is wasteful and burdensome for companies, with only 12 pharmaceutical oligonucleotides having reached the market to date and hundreds more being developed in medical studies and preclinical research. Thus, waste from the reverse phase purification process includes the disposal of hazardous waste. For example, solvent recovery is economically and environmentally beneficial at high production volumes, but approximately 50% of the waste volume still needs to be disposed of as water-rich hazardous waste.
- Complex manufacturing procedure
- Mandatory BPF Guidelines and Marketing Licenses
Marché de l'API à l'oligonucléotide : principales conclusions
Segmentation de l'API de l'oligonucléotide
End user (pharmaceutical companies, biotechnology companies)
The global oligonucleotide API market is segmented and analyzed for demand and supply by end user in pharmaceutical companies and biotechnology companies. Among these two segments, the pharmaceutical companies segment is estimated to account for the largest market share during the forecast period. The growth of the segment can be attributed to the increasing adoption of innovative technologies by pharmaceutical giants to improve drug efficacy and reduce development costs. For instance, a variety of oligonucleotides have become increasingly popular in the pharmaceutical industry, including antisense oligonucleotides, short interfering RNAs, helix switch oligonucleotides, microRNAs, immunostimulatory oligonucleotides, aptamers. The ability to target the disease gene or the messenger RNAs (mRNAs) encoded by it has created new therapeutic possibilities. Therapeutic antisense oligonucleotides (ASOs) range in length from 18 to 30 base pairs (bp).
API Type {Short Interfering RNA (siRNA), Antisense Oligonucleotides, Phosphorodiamidate Morpholino Oligonucleotides (PMO), Aptamers, CpG Oligonucleotides, MIRNA APIs}
The global oligonucleotide API market is also segmented and analyzed for demand and supply by type into short interfering RNA (siRNA), antisense oligonucleotides, phosphorodiamidate morpholino oligonucleotides (PMOs), aptamers, CpG oligonucleotides, MiRNA APIs, etc. Among these segments, the antisense oligonucleotides segment is expected to garner a significant share. The growth of the segment can be attributed to the increasing focus on personalized medicine across the globe, as well as the high efficacy of antisense in achieving effective results in treatment. In addition, the antisense oligonucleotide
Effective Results Alzheimer Treatment . Thus, Alzheimer cases are another factor that is expected to drive the growth of the segment in the coming years. This is expected to create ample opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By API type |
|
|
According to the commercial status |
|
|
By End User |
|
Souhaitez-vous personnaliser ce rapport de recherche selon vos besoins ? Notre équipe de recherche couvrira les informations dont vous avez besoin pour vous aider à prendre des décisions commerciales efficaces.
Personnaliser ce rapportIndustrie des API d'oligonucléotides - Synopsis régional
North American Market Forecast
The North American oligonucleotide API market, among all other regions, is expected to hold the largest market share by the end of 2035. The market growth can be primarily attributed to the increasing healthcare expenditure, along with the improvement in healthcare facilities anticipated to fuel the oligonucleotide API market in the region during the forecast period. A recent report by the Centers for Medicare & Medicaid Services revealed that approximately 19.7% of the U.S. GDP was spent on healthcare services in 2020, amounting to $4.1 trillion in total. Furthermore, increasing R&D investments in novel drug discovery and commercialization of oligonucleotide therapies are expected to further drive the regional market during the forecast period.
European Market Forecast
Furthermore, the European oligonucleotide API market is also expected to exhibit lucrative market growth by the end of 2035. The market growth can be attributed to the increasing investments in research and development activities in the region, followed by the presence of major players in the region. For instance, the biopharmaceutical sector in Europe generated approximately USD 21 billion in 2018 and this amount increased by nearly 26% to reach USD 28 billion in 2019. Furthermore, the increasing focus on developing precision medicine for cancer is another major factor that is expected to further drive the market growth throughout the forecast period in the region.
Entreprises dominant l'oligonucléotide Paysage API
- Ionis Pharmaceuticals, Inc.
- Company Overview
- Operational strategy
- Main products offered
- Financial results
- Key performance indicators
- Risk analysis
- Recent development
- Regional presence
- SWOT Analysis
- Jazz Pharmaceuticals plc
- BIOGEN INC.
- Sarepta Therapeutics, Inc.
- Alnylam Pharmaceuticals, Inc.
- Corden Pharma International GmbH
- Nitto Denko Avecia, Inc.
- Merck KGaA
- Ajinomoto Co., Inc.
- Kaneka Eurogentec SA
In the News
-
Ionis Pharmaceuticals, Inc. in collaboration with Biogen Inc., announced results from the study of the use of antisense oligonucleotide (ASO) in people with C9orf72-associated amyotrophic lateral sclerosis (ALS).
-
Jazz Pharmaceuticals plc announced that its Zepzelca (Lurbincedine) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-based chemotherapy.
Crédits des auteurs: Radhika Pawar
- Report ID: 4308
- Published Date: Feb 22, 2023
- Report Format: PDF, PPT
